Navigation Links
Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors

The US-based National Cancer Institute (NCI) has commended Novartis' anti-cancer tablet, Gleevec, as an// effective therapy for patients suffering from GISTs, metastatic gastro-intestinal tumors.

These tumours do have a rather complicated name. They are found in the digestive system - the gastrointestinal tract. They develop from cells of connective tissues that control the movements of the gut.

The tissues that support body organs are called the 'stroma', so that's where the stromal bit comes from. Cancers of connective tissues are 'sarcomas'. So the full name is gastrointestinal stromal sarcoma.

Some GISTS are benign (not cancerous) but they can become cancerous if not treated. Generally speaking, the larger the GIST, the more likely it is to be cancerous. It is estimated that approximately 5,000 to 6,000 new patients are diagnosed with GIST each year in the United States.

The NCI said that preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary GIST, showed that patients who received imatinib mesylate (Gleevec) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib. There was no recurrence of cancer in approximately 97 per cent of patients given Gleevec for a year after surgery to remove tumors, compared to approximately 83 per cent of those who underwent surgery but received a placebo.

The Novartis has lately come under a lot of fire over its continuing battle in Indian courts to patent Gleevec. In such a backdrop, the NCI's preliminary findings should be welcome for it.

Novartis supplied Gleevec for use in the study involving 600 patients, and also provided partial funding under a cooperative research and development agreement with NCI to support the clinical development of Gleevec.

"These results have major implica tions for patients with primary GIST," noted the principal investigator of the study, Ronald DeMatteo, Memorial Sloan-Kettering Cancer Center at New York.

"Conventional chemotherapy agents have been notoriously ineffective in GIST. This study for the first time demonstrated that targeted molecular therapy reduces the rate of recurrence after complete removal of a primary GIST."

Diane Young, Head of Global Medical Affairs at Novartis Oncology, said, "With these new data, we see that Gleevec may help patients with early GIST. We will now work with the investigators on a submission to gain regulatory approval for Gleevec as adjuvant treatment for GIST."

Adjuvant therapy is treatment given in addition to the primary therapy to kill any cancer cells that may have spread, even if the spread cannot be detected by radiologic or laboratory tests.
GPL/V
'"/>




Related medicine news :

1. Novartis files application with FDA for Zometa
2. Canine Painkiller unveiled by Novartis
3. Glivec the hot cancer drug from Novartis
4. Zometa [Novartis Drug] For Treatment Of Paget’s Diseas
5. Novartis MS Drug Shows Promising Results
6. Bird-flu Vaccine Adjuvant Contract Goes to Novartis
7. Drop Patent Petition, Activists Ask Novartis
8. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
9. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
10. Novartis Drug Diovan Shows Superior Benefits
11. Gleevec gets hopeful results
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/21/2017)... TX (PRWEB) , ... April 21, 2017 , ... ... Care products, announced an exciting new partnership with the highly regarded and well ... Airway Management’s highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will ...
(Date:4/21/2017)... Malvern, Worcestershire, UK (PRWEB) , ... April 21, ... ... Queen’s Award for Enterprise in the category of International Trade, the UK’s most ... performance in international trade, which represents 95% of total revenues and has grown ...
(Date:4/21/2017)... Ramon, CA (PRWEB) , ... April 21, 2017 , ... ... might not understand the estate planning process, or where to even begin. “Now more ... unresolved if you are to properly protect yourself and your family,” said attorney Lisa ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Westside Dental ... personalized dental care since 1985. After thirty-two years, Dr. Latner has become one of ... help my numerous clients over the years with all their dental needs,” said Dr. ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Each year, ... is a day to clean, plant trees and look forward to a better future. ... just about doing something outdoors. Indoor air quality can be two to five times ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
Breaking Medicine Technology: